Clinical Trial Update: A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma [Phase 1]

View source ↗

Summary

Ongoing Phase 1 study evaluating HC-7366 in combination with belzutifan (Welireg) for renal cell carcinoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• HC-7366
• Welireg (belzutifan)

Snippet

Sponsor: HiberCell, Inc. | Conditions: Renal Cell Carcinoma | Phase 1 | Status: RECRUITING